Author:
Murphy Michael V.,Du Dongyi (Tony),Hua Wei,Cortez Karoll J.,Butler Melissa G.,Davis Robert L.,DeCoster Thomas,Johnson Laura,Li Lingling,Nakasato Cynthia,Nordin James D.,Ramesh Mayur,Schum Michael,Von Worley Ann,Zinderman Craig,Platt Richard,Klompas Michael
Abstract
Objective.To explore the feasibility of identifying anterior cruciate ligament (ACL) allograft implantations and infections using claims.Design.Retrospective cohort study.Methods.We identified ACL reconstructions using procedure codes at 6 health plans from 2000 to 2008. We then identified potential infections using claims-based indicators of infection, including diagnoses, procedures, antibiotic dispensings, specialty consultations, emergency department visits, and hospitalizations. Patients’ medical records were reviewed to determine graft type, validate infection status, and calculate sensitivity and positive predictive value (PPV) for indicators of ACL allografts and infections.Results.A total of 11,778 patients with codes for ACL reconstruction were identified. After chart review, PPV for ACL reconstruction was 96% (95% confidence interval [CI], 94%–97%). Of the confirmed ACL reconstructions, 39% (95% CI, 35%–42%) used allograft tissues. The deep infection rate after ACL reconstruction was 1.0% (95% CI, 0.7%–1.4%). The odds ratio of infection for allografts versus autografts was 0.41 (95% CI, 0.19–0.78). Sensitivity of individual claims-based indicators for deep infection after ACL reconstruction ranged from 0% to 75% and PPV from 0% to 100%. Claims-based infection indicators could be combined to enhance sensitivity or PPV but not both.Conclusions.While claims data accurately identify ACL reconstructions, they poorly distinguish between allografts and autografts and identify infections with variable accuracy. Claims data could be useful to monitor infection trends after ACL reconstruction, with different algorithms optimized for different surveillance goals.Infect Control Hosp Epidemiol 2014;35(6):652–659
Publisher
Cambridge University Press (CUP)
Subject
Infectious Diseases,Microbiology (medical),Epidemiology
Reference40 articles.
1. Food and Drug Administration (FDA). Guidance for Industry: MedWatch Form FDA 3500A: Mandatory Reporting of Adverse Reactions Related to Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). Silver Spring, MD: FDA, 2005. http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatorinformation/guidances/tissue/ucm074000.htm. Accessed October 19, 2011.
2. Transmission of Elizabethkingia meningoseptica (Formerly Chryseobacterium meningosepticum) to Tissue-Allograft Recipients
3. Using Automated Health Plan Data to Assess Infection Risk from Coronary Artery Bypass Surgery
4. The Safe and Effective Use of Allograft Tissue—An Update
5. Update: allograft-associated bacterial infections—United States, 2002;MMWR Morb Mortal Wkly Rep,2002
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献